

CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome	Francesco Dotta
Qualifica	Professore Ordinario di Endocrinologia
Amministrazione	Università di Siena
Incarico attuale	Direttore del Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Università di Siena. Delegato del Rettore alla Sanità. Direttore dell'Area Assistenza Ricerca Clinica e Traslazionale del Dipartimento Innovazione, Sperimentazione e Ricerca Clinica e Traslazionale, Azienda Ospedaliera Universitaria Senese. Direttore dell'Unità Operativa Complessa di Diabetologia, Dipartimento Innovazione, Sperimentazione e Ricerca Clinica e Traslazionale, Azienda Ospedaliera Universitaria Senese. Direttore dell'UOSA di Dietetica Medica, Dipartimento Innovazione, Sperimentazione e Ricerca Clinica e Traslazionale, Azienda Ospedaliera Universitaria Senese.

TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE

Titolo di studio	Laurea in Medicina e Chirurgia
Specializzazioni	Specializzazione in Endocrinologia
Iscrizioni ad albi professionali	Ordine dei Medici-Chirurghi ed Odontoiatri di Roma
Altri titoli di studio e professionali	Abilitazione Scientifica Nazionale settore concorsuale 06/D2 Endocrinologia, Nefrologia e Scienze dell'Alimentazione e del Benessere – I Fascia Abilitazione Scientifica Nazionale settore concorsuale 06/B1 Medicina Interna – I Fascia Direttore della Scuola di Specializzazione di Endocrinologia e Malattie del metabolismo, Università di Siena. Professore Associato Confermato , Raggruppamento disciplinare MED/13-Endocrinologia, Facoltà di Medicina e Chirurgia, Dipartimento di Scienze Mediche Chirurgiche e Neuroscienze, Università di Siena.

	<p>Direttore del Centro Studi e Ricerche dell'Health City Institute.</p> <p>Presidente dell'Osservatorio regionale per la formazione medico-specialistica.</p> <p>Presidente dell'Osservatorio regionale per la formazione medico-specialistica.</p> <p>Membro del Consiglio Direttivo SIE.</p> <p>Coordinatore della Commissione Terapie Innovative della SIE.</p> <p>Membro della Commissione prevista dall'art. 13, comma 4, della LR 40/2005 per il supporto alla predisposizione del protocollo d'intesa tra Regione Toscana e Università.</p> <p>Membro del Comitato Tecnico Scientifico del CREA Sanità - Consorzio per la Ricerca Economica Applicata in Sanità.</p> <p>Componente della Commissione Relazioni Internazionali per l'Area 2 - Scienze Biomediche e Mediche, Università di Siena.</p> <p>Segretario Generale della Commissione Scientifica dell'Italian Barometer Diabetes Observatory.</p> <p>Membro della Commissione Biologi, Biotecnologi e Corsi Basic Science della Società Italiana di Endocrinologia.</p> <p>Membro del Gruppo di lavoro sull'internazionalizzazione di Ateneo, Università di Siena.</p> <p>Presidente della Fondazione di Ricerca Biomedica "Umberto Di Mario" ONLUS.</p>
<p>Esperienze professionali (incarichi ricoperti)</p>	<p>Componente Senato Accademico come rappresentante dei Direttori di Dipartimento Area 2 – Scienze Biomediche e Mediche.</p> <p>Membro del Gruppo di lavoro dell'ANVUR per gli Indicatori di terza missione.</p> <p>Coordinatore della Commissione Scientifica della Società Italiana di Diabetologia.</p> <p>Membro del Consiglio Direttivo della Società Italiana di Diabetologia.</p> <p>Membro della Commissione Scientifica della Società Italiana di Diabetologia.</p> <p>Professore Associato, Raggruppamento disciplinare MED/13-Endocrinologia, Ia Facoltà di Medicina e Chirurgia, Dipartimento di Scienze Cliniche, Università degli Studi di Roma "La Sapienza".</p> <p>Ricercatore Confermato, Raggruppamento disciplinare F07E-Endocrinologia, Ia Facoltà di Medicina e Chirurgia, Dipartimento di Scienze Cliniche, Università degli Studi di Roma "La Sapienza".</p> <p>Dirigente Medico di I livello presso la Divisione di Endocrinologia, Dipartimento di Scienze Cliniche, Policlinico Umberto I, Università "La Sapienza", Roma.</p> <p>Funzionario Tecnico di ruolo presso la Cattedra di Medicina Costituzionale ed Endocrinologia, Università degli Studi di Roma "La Sapienza".</p> <p>Ricercatore in Medicina presso la Harvard University, School of Medicine, Boston, MA - Usa.</p> <p>Ricercatore presso il Joslin Diabetes Center, Boston, MA - USA.</p>
<p>Capacità linguistiche</p>	<p>Ottima conoscenza della lingua inglese.</p>
<p>Capacità nell'uso delle tecnologie</p>	<p>Buone conoscenze relative agli applicativi Office e all'utilizzo dei software online gestione dati area biomedica.</p>
<p>Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed</p>	<p style="text-align: center;">ATTIVITÀ IN RIVISTE SCIENTIFICHE</p>

ogni altra informazione che il dirigente ritiene di dover pubblicare)

Associate Editor di Nutrition, Metabolism & Cardiovascular Diseases (2005-2011).
Academic Editor di PLoS ONE (dal 2011).
Membro dell'Editorial Board del Journal of Clinical Endocrinology and Metabolism (2005-2009).
Membro dell'Editorial Board del World Journal of Diabetes (dal 2010).
Membro dell'Editorial Board di Acta Diabetologica (dal 2007).
Membro dell'Editorial Board di Journal of Endocrinological Investigation (2009-2011).

Referee delle seguenti riviste scientifiche:

Proceedings of the National Academy of Sciences USA, Diabetes, Diabetologia, Molecular Metabolism, Journal of Clinical Endocrinology and Metabolism, Endocrinology, Molecular Endocrinology, Cell Death and Differentiation, European Journal of Immunology, Clinical Immunology, European Journal of Endocrinology, Diabetes Metabolism Research and Reviews, Diabetes Obesity & Metabolism, Cell Death and Differentiation, Clinical Immunology, Diabetes Metabolism Research and Reviews, Nutrition Metabolism and Cardiovascular Diseases, Transplantation, Journal of Autoimmunity, Journal of Endocrinological Investigation, Hormone Research, Clinical Chemistry, Autoimmunity, Acta Diabetologica, PLoS ONE, American Journal of Medicine.

PUBBLICAZIONI

Amenta F, Cavallotti C, Dotta F, Ferrante F, Spinelli F, Vatrella F. (1983) The autonomic innervation of the human greater saphenous vein. Acta Histochem; 72: 111-116. (I.F. 1.719)

Di Mario U, Scardellato A, Dotta F, Kennedy R, Pozzilli, Andreani D. (1985) T cell phenotype in recent onset and relapsed Graves' disease patients before therapy. In: "Endocrinology '85". Molinatti GM and Martini L (eds), Elsevier Science Publishers BV: 463-467.

Di Mario U, Vitillo M, Cavatorta F, Scardellato A, Dotta F, Sutherland J, Pozzilli P, Andreani D. (1986) Monitoring immunopathological events in Graves' patients: humoral vs. cellular immune factors as markers of disease activity. In: "The thyroid and autoimmunity". Drexhage HA and Wiersinga WM (eds), Elsevier Science Publishers BV: 64-67.

Gargiulo P, Di Mario U, Dotta F, Kennedy R, Guy K, Pachì A, Fallucca F. (1986) Activated T cells in normal pregnant women and neonates. Eur J Obstet Gyn RB; 23: 127-135. (I.F. 2.024)

Di Mario U, Dotta F, Gargiulo P, Sutherland J, Andreani D, Guy K, Pachì A, Fallucca F. (1987) Immunology in diabetic pregnancy: activated T cells in diabetic mothers and neonates. Diabetologia; 30(2): 66-71. (I.F. 7.113)

Dotta F, Gargiulo P, Tiberti C, Pachi A, Fallucca F, Andreani D, Di Mario U. (1987) Humoral and cellular immune abnormalities in neonates of diabetic mothers: any pathological role? Exp Clin Endocr Diab; 89(3): 333-339. (I.F. 1.927)

Di Mario U, Dotta F, Gargiulo P, Fallucca F, Pachì A, Andreani D. (1987) Immunopathology of diabetic mothers and their infants: a

contribution to the understanding of islet autoimmunity. In: "The immunology of diabetes". Jaworski (ed), Elsevier Science Publisher B.V.: 137-142.

Dib SA, Colman PG, Dotta F, Tautkus M, Rabizadeh A, Eisenbarth GS. (1987) Expression of cytoplasmic islet cell antigens by rat pancreas. *Diabetes*; 36(8): 982-985. (I.F.7.199)

Di Mario U, Cavatorta F, Scardellato A, Dotta F, Vitillo M, Andreani D (1987) Immunological parameters in patients with Graves' disease before treatment. In: Bianchi (ed), "Thyroid function and dysfunction: Modern concepts", 447-451.

Dotta F, Nayak RC, Dib SA, Di Bella E, Krisch K, Posillico JT, Ricker AT, Di Mario U, Eisenbarth GS. (1988) A novel neuroendocrine cell surface glycoprotein: identification, isolation and initial characterization. *Endocrinology*; 122(4): 1263-1268. (I.F. 3.800)

Di Mario U, Dotta F, Crisa L, Anastasi E, Andreani D, Dib SA, Eisenbarth GS. (1988) Circulating anti-immunoglobulin antibodies in recent-onset type 1 diabetic patients. *Diabetes*; 37(4): 462-466. (I.F.7.199)

Eisenbarth GS, Vardi, Ziegler AG, Colman PG, Nayak RC, Dotta F, Jackson RA, Fujii S, Ricker AT, Rabinowe SL, Ikegami H, Soeldner S, Hattori M. (1988) Lessons from the NOD mouse and the BB rat: similarities and contrasts. In: "Animal models in diabetes". Renold AE and Shafrir E (eds); John Libbey, London: 120-123.

Colman PG, Di Mario U, Rabizadeh A, Dotta F, Anastasi E, Eisenbarth GS. (1988) A prozone phenomenon interferes in islet cell antibody detection: direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. *J Autoimmun*; 1(2): 109- 117. (I.F. 7.543)

Dib SA, Colman PG, Dotta F, Tautkus M, Rabizadeh A, Eisenbarth GS. (1988) Assay for cytoplasmic islet cell antibodies using two-color immunofluorescence and rat pancreas. *Adv Exp Med Biol*; 246: 63-67. (I.F. 2.126)

Dotta F, Eisenbarth GS. (1989) Type 1 diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction. *Clin Immunol*; 50: 85-95. (I.F. 3.548)

Dotta F, Colman PG, Lombardi D, Scharp DW, Andreani D, Pontieri GM, Di Mario U, Lenti L, Eisenbarth GS, Nayak RC. (1989) Ganglioside expression in human pancreatic islets. *Diabetes*; 38(11): 1478-1483. (I.F. 7.199)

Gardner SL, Dotta F, Nayak RC, George KL, Eisenbarth GS, Halban PA. (1989) Modulation by sodium butyrate of the differentiated status of a clonal pancreatic B-cell line (RIN). *Diabetes Res Clin PR*; 12(2): 93-99. (I.F. 3.239)

Russo E, Jackson RA, Dotta F, Lipos MA, Castano L, Eisenbarth GS. (1990) Type 1 diabetes as a "Mendelian" and "regulated" immune process. in: "Molecular biology of autoimmunity". A.G. Demaine, J. Banga, A.M.McGregor (eds); Springer-Verlag, London: 351-362.

Eisenbarth GS, Jackson RA, Ziegler R, Castano L, Bleich D, Dotta F. (1990) Predizione e prevenzione del diabete di tipo 1. *Il Diabete*; 2: 29-34.

Dotta F, Pozzilli P. (1990) Are islet cell antigens gangliosides? *Intl*

Diab Monitor; 2: 2-3.

Previti M, Dotta F, Anastasi E, Gianani R, Lenti L, Pontieri GM, Di Mario U. (1991) Autoimmunità insulare nel ratto BB: I gangliosidi pancreatici del ceppo diabete-prono (DP) differiscono da quelli del diabete-resistente (DR). *Il Diabete*; 3: 309-311.

Anastasi E, Perfetti R, Tiberti C, Crisà L, Cabrera E, Dotta F, Di Mario U, Andreani D. (1991) Gli autoanticorpi anti-insulina sono realmente indicatori di diabete mellito di tipo 1? *Il Diabete*; 3: 357-360.

Dotta F, Previti M, Lenti L, Tiberti C, Anastasi E, Pontieri GM, Appel MC, Andreani D, Di Mario U (1991) Attività beta cellulare ed espressione antigenica nel pancreas di ratto: identificazione di un ganglioside metabolicamente regolabile. *Il Diabete*; 3: 365-367.

Dotta F. (1991) Gangliosidi pancreatici, anticorpi polari ed autoimmunità β cellulare. *Il Diabete*; 3: 254-257.

Dotta F. (1991) Anti-glucose transporter molecole(s) autoimmunity in type 1 diabetes? *Diab Prev Ther*; 5: 3-4.

Dotta F, Peterson LB, Previti M, Metzger J, Tiberti C, Anastasi E, Zoppitelli, Wicker LS, Di Mario U. (1992) Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction. *Endocrinology*; 130(1): 37- 42. (I.F. 3.800)

Rotella C, Dotta F, Mannucci E, Di Mario U. (1992) Autoantigens in thyroid and islet autoimmunity: similarities and differences. *Autoimmunity*; 12(3): 223-237. (I.F. 2.403)

Previti M, Dotta F, Pontieri GM, Di Mario U, Lenti L. (1992) Determination of gangliosides by high-performance liquid chromatography with photodiode-array detection. *J Chromatogr A*; 605: 221-225. (I.F. 3.858)

Wicker LS, Appel MC, Dotta F, Pressey A, Miller BJ, DeLarato NH, Fischer PA, Boltz RC, Peterson LB. (1992) Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulinitis and cyclophosphamide-induced diabetes. *J Exp Med*; 176(1): 67-77. (I.F. 10.892)

Pozzilli P, Buzzetti R, Dotta F, Andreani D. (1992) Acute onset of seeming IDDM in an AIDS patient. *Diabetes Care*; 15(11): 1824-1825. (I.F. 15.270)

Di Mario U, Dotta F, Purrello F. (1992) Storia naturale del diabete di tipo 1 in fase preclinica. *Il Diabete*; 4: 283-86.

Cavallo MG, Dotta F, Monetini L, Baroni MG, Toto A, Pozzilli P. (1992) Caratterizzazione antigenica di una linea cellulare di insulinoma umano e sua utilizzazione per la valutazione degli anticorpi anti-isola pancreatica. *Il Diabete*; 4, Suppl.1: 71-74.

Previti M, Dotta F, Tiberti C, Anastasi E, Lenti L, Pontieri GM, Andreani D, Di Mario U. (1992) Identificazione del ganglioside insulare GM2-1: similitudini con un autoantigene neuronale. *Il Diabete*; 4, Suppl.1: 91-94.

Di Mario U, Dotta F. (1992) Natural history and prediction of type 1 diabetes. *Ann Ig*; 4(3): 153-157.

Dotta F, Tiberti C, Previti M, Anastasi E, Andreani D, Lenti L, Pontieri

GM, Gianani R, Appel MC, Eisenbarth GS, Di Mario U. (1993) Rat pancreatic ganglioside expression: differences between a model of autoimmune islet B cell destruction and a normal strain. *Clin Immunol Immunopathol*; 66(2): 143-149. (I.F. 3.548)

Anastasi E, Tiberti C, Sensi M, Ponte E, Filippetti R, Dotta F, Vecci E, Fiori MG, Di Mario U. (1993) Pancreatic gangliosides delay the onset of insulinitis and hyperglycaemia in the low-dose streptozotocin mouse model. *Scand J Immunol*; 37(3): 308-313. (I.F. 2.563)

Dotta F, Dionisi S, Lollobrigida L, Previti M. (1993) Autoanticorpi ed autoantigeni in un modello animale di distruzione β cellulare: il topo NOD. *Giornale It. Diabetol*; Suppl.1: 63-68.

Boccuni ML, Bosi E, Buzzetti R, Calafiore R, Cavallo MG, Di Mario U, Dotta F, Giordano C, Pozzilli P, Previti M, Richiusa P, Scorsone A, Signore A, Visalli N. (1993) Immunologia ed immunoterapia del diabete mellito di tipo 1. *Il Diabete*; 5 (Suppl.1): 1-44.

Di Mario U, Dotta F. (1993) Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. *Diabetes-Metab Res Rev*; 9(4): 245-249. (I.F. 4.758)

La Mancusa R, Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C, Dotta F, Tarquini S, Simeoni S, Pettrossi G, Vieri M, Di Palma P, Cara D, Scodanibbio C, Maurelli M, Ferro D, Saliola M, Pulcinelli F, Riondino S. (1994) Hypercoagulability state in patients with chronic obstructive pulmonary disease. *Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost*; 72: 343-346. (I.F. 4.733)

Dotta F, Anastasi E, Tiberti C, Di Mario U. (1994) Autoantigens in type 1 diabetes mellitus. *J Endocrinol Invest*; 17(7): 497-508. (I.F. 3.439)

Dionisi S, Dotta F. (1994) Can we replace cytoplasmic ICA determination in diabetes prediction? *Diab Prev Ther*; 8: 36-37.

Tiberti C, Dotta F, Anastasi E, Torresi P, Multari G, Vecci E, Andreani D, Di Mario U. (1995) Anti-ganglioside antibodies in new onset type 1 diabetic patients and high risk subjects. *Autoimmunity*; 22(1): 43-48. (I.F. 2.403)

Dotta F, Previti M, Lenti L, Dionisi S, Casetta B, D'Erme M, Eisenbarth GS, Di Mario U. (1995) GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. *Diabetologia*; 38(9): 1117-1121. (I.F. 7.113)

Dotta F, Di Mario U. (1996) Antigenic determinants in type 1 diabetes mellitus. Review article. *APMIS*; 104(11): 769-774. (I.F. 2.225)

Dotta F, Gianani R, Previti M, Lenti L, Dionisi S, D'Erme M, Eisenbarth GS, Di Mario U. (1996) Autoimmunity to the GM2-1 islet ganglioside before and the onset of type 1 diabetes. *Diabetes*; 45(9): 1193-1196. (I.F. 7.199)

Mennuni C, Santini C, Dotta F, Farilla L, Di Mario U, Fierabracci A, Bottazzo G, Cortese R, Luzzago A. (1996) Selection of phage-displayed peptides mimicking type 1 diabetes-specific epitopes. *J Autoimmun*; 9(3): 431-436. (I.F. 7.543)

Cavallo MG, Dotta F, Monetini L, Dionisi S, Previti M, Valente L, Toto A, Di Mario U, Pozzilli P. (1996) Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta

cells. *J Endocrinol*; 150(1): 113-120. (I.F. 4.381)

Dotta F, Di Mario U. (1996) Il diabete mellito di tipo 1 in Sardegna. *Scienza e Diabete*; 6: 6-7.

Dotta F, Dionisi S, Farilla L, Di Mario U. (1996) The use of immunological markers in IDDM after more than 20 years from ICA description. *Diabetes-Metab Rev Res*; 12(2): 121-126. (I.F. 4.758)

Dotta F, Dionisi S, Misasi R, Tiberti C, Anastasi E, Carabba B, Farilla L, Di Mario U. (1996) Ganglioside antigens in autoimmune diabetes. *Diabetes Nutr Metab*; 9: 215-220. (I.F. 0.719)

Dotta F. (1996) Highlights from the American Diabetes Association's Symposium on prevention of type 1 diabetes in the general population. *Diab Prev Ther*; 10: 28-29.

Misasi R, Dionisi S, Farilla L, Carabba B, Lenti L, Di Mario U, Dotta F. (1997) Gangliosides and autoimmune diabetes. *Diabetes-Metab Rev Res*; 13(3): 163-179. (I.F. 4.758)

Dotta F, Falorni A, Tiberti C, Dionisi S, Anastasi E, Torresi P, Lernmark A, Di Mario U. (1997) Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset. *J Autoimmun*; 10(6): 585-588. (I.F. 7.543)

Tiberti C, Falorni A, Torresi P, Vecci E, Anastasi E, Dotta F, Di Mario U. (1997) A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. *J Immunol Methods*; 207(2): 107-113. (I.F. 1.913)

Mennuni C, Santini C, Lazzaro D, Dotta F, Farilla L, Fierabracci A, Bottazzo GF, Di Mario U, Cortese R, Luzzago A. (1997) Identification of a novel type 1 diabetes-specific epitope by screening phage libraries with sera from pre-diabetic patients. *J Mol Biol*; 268(3): 599-606. (I.F. 5.067)

Dionisi S, Dotta F, Diaz-Horta O, Carabba B, Viglietta V, Di Mario U. (1997) Target antigens in autoimmune diabetes: pancreatic gangliosides. *Ann I Super Sanità*; 33(3): 433-435. (I.F. 2.172)

Dotta F, Previti M, Neerman-Arbez M, Dionisi S, Cucinotta D, Lenti L, Di Mario U, Halban PA. (1998) The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not beta-cell specific. *Endocrinology*; 139(1): 316-319. (I.F. 3.800)

Di Mario U, Dotta F. (1998) Beta-cell autoimmunity 1998. *Diabetes-Metab Res Rev*; 14(1): 1-2. (I.F. 4.758)

Anastasi E, Dotta F, Tiberti C, Vecci E, Ponte E, Di Mario U. (1999) Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose Stz mouse model of diabetes. *Autoimmunity*; 29(4): 249-256. (I.F. 2.403)

Dotta F, Dionisi S, Viglietta V, Tiberti C, Matteoli MC, Cervoni M, Bizzarri C, Marietti G, Testi M, Multari G, Lucentini L, Di Mario U. (1999) T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. *Eur J Endocrinol*; 141(3): 272-278. (I.F. 5.107)

Anastasi E, Ponte E, Gradini R, Bulotta A, Sale P, Tiberti C, Okamoto H, Dotta F, Di Mario U. (1999) Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. *Eur J Endocrinol*; 141(6): 644-652. (I.F. 5.107)

Dotta F, Santangelo C, Dionisi S, Viglietta V, Vendrame F, Di Mario U. (1999) Linfociti T, autoreattività e apoptosi: basi immunopatogenetiche del diabete di tipo 1. *Il Diabete*; 11 (Suppl.): 3-5.

Tiberti C, Buzzetti R, Anastasi E, Dotta F, Vasta M, Petrone A, Cervoni M, Torresi P, Vecci E, Multari G, Di Mario U. (2000) Autoantibody negative new onset of type 1 diabetic patients lacking high risk HLA alleles in a caucasian population: are these type 1b diabetes cases? *Diabetes-Metab Res Rev*; 16(1): 8-14. (I.F. 4.758)

Marchetti P, Dotta F, Ling Z, Lupi R, Del Guerra S, Santangelo C, Realacci M, Marselli L, Di Mario U, Navalesi R. (2000) Function of pancreatic islets isolated from a type 1 diabetic patient. *Diabetes Care*; 23(5): 701-703. (I.F. 15.270)

Cilio CM, Bosco S, Moretti C, Farilla L, Savignoni F, Colarizi P, Multari G, Di Mario U, Bucci G, Dotta F. (2000) Congenital autoimmune diabetes mellitus. *New Engl J Med*; 342(20): 1529-1531. (I.F. 70.670)

Farilla L, Dotta F, Di Mario U, Rapoport B, McLachlan SM. (2000) Presence of interleukin 4 or interleukin 10, but not both cytokines, in pancreatic tissue of two patients with recently diagnosed diabetes mellitus type I. *Autoimmunity*; 32(3): 161-166. (I.F. 2.403)

Del Guerra S, Lupi R, Dotta F, Marselli L, Lencioni C, Santangelo C, Realacci M, Carmellini M, Mosca F, Navalesi R, Marchetti P. (2000) Effects of prolonged exposure to pancreatic glucagon on the function, antigenicity and survival of isolated human islets. *Diabetes-Metab Res Rev*; 16(4): 281-286. (I.F. 4.758)

Dotta F. (2000) Meccanismi patogenetici nel diabete autoimmune a lenta insorgenza. *Il Diabete*; 12: 109-112.

Piro S, Lupi R, Dotta F, Patanè G, Rabuazzo MA, Marselli L, Santangelo C, Realacci M, Del Guerra S, Purrello F, Marchetti P. (2001). Bovine islets are less susceptible than human islets to damage by human cytokines. *Transplantation*; 71(1): 21-26. (I.F. 4.593)

Marselli L, Dotta F, Piro S, Santangelo C, Masini M, Lupi R, Realacci M, Del Guerra S, Mosca F, Boggi U, Purrello F, Navalesi R, Marchetti P. (2001) Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. *J Clin Endocr Metab*; 86(10): 4974-4978. (I.F. 5.605)

Trincavelli ML, Marselli L, Falleni A, Gremigni V, Ragge E, Dotta F, Santangelo C, Marchetti P, Lucacchini A, Martini C. (2002) Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. *J Cell Biochem*; 84(3): 636-644. (I.F. 3.448)

Miao D, Yu L, Tiberti C, Cuthbertson DD, Rewers M, Di Mario U, Eisenbarth GS, Dotta F. (2002) ICA512 (IA-2) epitope specific assays distinguish transient from diabetes associated autoantibodies. *J Autoimmun*; 18(2): 191-196. (I.F. 7.543)

Dotta F, Vendrame F. (2002) Neonatal syndromes of polyendocrinopathy. *Endocrin Metab Clin North Am*; 31(2): 283-293. (I.F. 3.306)

Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, Patané G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario

U, Del Prato S, Marchetti P. (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. *Diabetes*; 51(5): 1437-1442. (I.F. 7.199)

Farilla L, Tiberti C, Luzzago A, Yu L, Eisenbarth GS, Cortese R, Dotta F, Di Mario U. (2002) Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512bdc dominant autoantigenic epitopes. *Eur J Immunol*; 32(5): 1420-1427. (I.F. 4.695)

Dotta F, Anastasi E. (2002) Nuove fonti di cellule produttrici di insulina. *Il Diabete*; 14: 128-133.

Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC; International Expert Panel. (2003) New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an International expert panel meeting. Barcelona, Spain, 19 february 2003. *Transplantation*; 75(10): 3-24. (I.F. 4.593)

Tiberti C, Bao F, Bonamico M, Verrienti A, Picarelli A, Di Tola M, Ferri M, Vecci E, Dotta F, Eisenbarth GS, Di Mario U. (2003) Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. *Clin Immunol Immunopathol*; 109(3): 318-324. (I.F. 3.548)

Lupi R, Marselli L, Dionisi S, Del Guerra S, Boggi U, Del Chiaro M, Lencioni C, Bugliani M, Mosca F, Di Mario U, Del Prato S, Dotta F, Marchetti P. (2004) Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. *Diabetes-Metab Res Rev*; 20(3): 246-251. (I.F. 4.758)

Hui H, Dotta F, Di Mario U, Perfetti R. (2004) Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. *J Cell Physiol*; 200(2): 177-200. (I.F. 4.522)

Falorni A, Laureti S, De Bellis A, Zanchetta R, Tiberti C, Arnaldi G, Bini V, Beck-Peccoz P, Bizzarro A, Dotta F, Mantero F, Bellastella A, Betterle C, Santeusano F; SIE Addison Study Group. (2004) Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. *J Clin Endocr Metab*; 89(4): 1598-1604. (I.F. 5.605)

Marselli L, Trincavelli L, Santangelo C, Lupi R, Del Guerra S, Boggi U, Falleni A, Gremigni V, Mosca F, Martini C, Dotta F, Di Mario U, Del Prato S, Marchetti P. (2004) The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. *Eur J Endocrinol*; 151(2): 207-214. (I.F. 5.107)

Dotta F, Marchetti P. (2004) Pathological changes in human insulinitis. *Curr Opin Endocrinol & Diabetes*; 11: 82-84. (I.F. 3.298)

Vendrame F, Zappaterreno A, Dotta F. (2004) Markers of beta cell function in type 1 diabetes mellitus. *Minerva Med*; 95(2): 79-84. (I.F. 2.475)

Vendrame F, Santangelo C, Misasi R, Dionisi S, Gizzi C, Realacci M, Grassetti D, Di Mario U, Dotta F. (2005) Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus. *Eur J Endocrinol*; 152(1): 119-125. (I.F. 5.107)

Santangelo C, Scipioni A, Marselli L, Marchetti P, Dotta F. (2005) Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. *Eur J Endocrinol*; 152(3): 485-489. (I.F. 5.107)

Putnam AL, Vendrame F, Dotta F, Gottlieb PA. (2005) CD4+CD25 high regulatory T cells in human autoimmune diabetes. *J Autoimmun*; 24(1): 55-62. (I.F. 7.543)

Tiberti C, Verrienti A, Fiore B, Yu L, Eisenbarth GS, Dotta F, Di Mario U. (2005) IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes. *Clin Immunol*; 115(3): 260-267. (I.F. 3.548)

Anastasi E, Santangelo C, Bulotta A, Dotta F, Argenti B, Mincione C, Gulino A, Maroder M, Perfetti R, Di Mario U. (2005) The acquisition of an insulin-secreting phenotype by HGF-treated rat pancreatic ductal cells (ARIP) is associated with the development of susceptibility to cytokine-induced apoptosis. *J Mol Endocrinol*; 34(2): 367-376. (I.F. 3.744)

Wilkinson A, Davidson J, Dotta F, Home P, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregrosa JV, Uchida K, Valentine F, Villamil F, Vincenti F, Wissing M. (2005) Guidelines for the treatment and management of new-onset diabetes after transplantation. *Clin Transplant*; 19(3): 291-298. (I.F. 1.667)

Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant, Dotta F. (2005) Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. *Diabetologia*; 48(8): 1565-1575. (I.F. 7.113)

Dotta F, Fondelli C, Vendrame F, Gianani R. (2005) Pathological changes in human islets. *Curr Opin Endocrinol & Diabetes*; 12: 285-290. (I.F. 3.298)

Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. (2005) Latent Autoimmune Diabetes in Adults (LADA) should be less latent. *Diabetologia*; 48(11): 2206-2212. (I.F. 7.113)

Dotta F, Fondelli C, Di Mario U. (2005) Type 1 diabetes mellitus as a polygenic multifactorial disease: immunopathogenic mechanisms of beta-cell destruction. *Acta Biomed*; 76 Suppl 3: 14-18.

Roep B, Van Halteren A, Boggi U, Marchetti P, Dotta F. (2005) Islet autoreactivity in pancreas draining lymph nodes in recent onset type 1 diabetes. *Endocr J*; 52: 162-164. (I.F. 1.940)

Tiberti C, Bonamico M, Dotta F, Verrienti A, Di Tola M, Liu E, Ferri M, Nenna R, Picarelli A, Eisenbarth GS. (2006) Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: a new tool to distinguish disease-specific immunoreactivities. *Clin Immunol*; 121(1): 40-46. (I.F. 3.548)

Vendrame F, Segni M, Grasseti D, Tellone V, Augello G, Trischitta V, Torlontano M, Dotta F. (2006) Impaired caspase-3 expression by peripheral T cells in chronic autoimmune thyroiditis and in autoimmune polyendocrine syndrome-2. *J Clin Endocr Metab*; 91(12):

5064-5068. (I.F. 5.605)

Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Onetti Muda A, Del Prato S, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P. (2007) Cocksackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. *PNatl Acad Sci USA*; 104(12): 5115-5120. (I.F. 9.580)

Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML Bazzigaluppi E, Dotta F, Bosi E. (2007) High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. *Diabetes Care*; 30(4): 932-938. (I.F. 15.270)

Gallo R, Gambelli F, Gava B, Sasdelli F, Tellone V, Masini M, Marchetti P, Dotta F, Sorrentino V. (2007) Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. *Cell Death Differ*; 14(11): 1860-1871. (I.F. 8.086)

Giannakakis K, Massella L, Grasseti D, Dotta F, Perez M, Onetti-Muda A. (2007) Type VII collagen in Alport syndrome. *Nephrol Dial Transpl*; 22(12): 3501-3507. (I.F. 4.198)

Marchetti P, Dotta F, Lauro D, Purrello F. (2008) An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. *Regul Peptides*; 146(1-3): 4-11. (I.F. 1.813)

Bolli G, Dotta F, Rochotte E, Cohen SE. (2008) Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab*; 10(1): 82-90. (I.F. 6.133)

Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, Dotta F, Sorrentino V. (2008) Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. *Diabetologia*; 51(7): 1296-1305. (I.F. 7.113)

Vendrame F, Verrienti A, Parlapiano C, Filetti S, Dotta F, Morano S. (2008) Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. *Ann Clin Biochem*; 45(Pt 2): 218-220. (I.F. 1.893)

Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, Cucinotta D, Galluzzo A, Falorni A, Dotta F. (2008) Identification of tyrosine phosphatase 2 (256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. *Diabetes*; 57(5): 1276-1283. (I.F. 7.199)

Bonato V, Barni R, Cataldo D, Collini A, Ruggieri G, De Bartolomeis C, Dotta F, Carmellini M. (2008) Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. *Transpl P*; 40(6): 1888-1890. (I.F. 0.959)

Bruno G, De Micheli G, Fedele D, Monge L, Bonomo M, Consoli A, De Cosmo S, Di Bartolo P, Di Benedetto A, Di Cianni G, Dotta F, Giaccari A, Giorgino F, Grassi G, Gruden G, Mannino D, Orlandini D, Ponziani MC, Vaccaro O, Vitacolonna E. (2008) Italian standards for diabetes mellitus 2007: executive summary. *Acta Diabetol*; 45: 107-127. (I.F. 2.996)

Gallo R, Grieco FA, Marselli L, Ferretti E, Gulino A, Marchetti P, Dotta F. (2008) Hedgehog signaling during expansion of human pancreatic islet-derived precursors. *Ann NY Acad Sci*; 1150: 43-45. (I.F. 4.295)

Dotta F, Fondelli C, Falorni A. (2008) Can NK cells be a therapeutic target in human type 1 diabetes? *Eur J Immunol*; 38(11): 2961-2963. (I.F. 4.695)

Dotta F. (2009) Innate immunity and human insulinitis during beta-cell Cocksackie B4 infection. *J Med Virol*; 81: 202. (I.F. 2.049)

Tiberti C, Shashaj B, Verrienti A, Vecci EG, Lucantoni F, Masotti D, Morano S, Sulli N, Dotta F. (2009) GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva. *Clin Immunol*; 131(2): 271-276. (I.F. 3.548)

Bosi E, Dotta F, Jia Y, Goodman M. (2009) Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. *Diabetes Obes Metab*; 11(5): 506-515. (I.F. 6.133)

Bolli G, Dotta F, Colin L, Minic B, Goodman M. (2009) Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Obes Metab*; 11(6): 589-595. (I.F. 6.133)

Bonato V, Cataldo D, Dotta F, Carmellini M. (2009) Diagnosis and approach to posttransplant diabetes. *Curr Diabetes Rep*; 9(4): 317-323. (I.F. 3.996)

La Marca A, Marzotti S, Brozzetti A, Stabile G, Artenisio AC, Bini V, Giordano R, De Bellis A, Volpe A, Falorni A; Italian Addison Network. (2009) Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. *J Clin Endocr Metab*; 94(10): 3816-23. (I.F. 5.605)

Brozzetti A, Marzotti S, Tortoioli C, Bini V, Giordano R, Dotta F, Betterle C, De Bellis A, Arnaldi G, Toscano V, Arvat E, Bellastella A, Mantero F, Falorni A; Italian Addison Network. (2010) Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. *Eur J Endocrinol*; 162(2): 361-369. (I.F. 5.107)

Roep BO, Kleijwegt FS, van Halteren AG, Bonato V, Boggi U, Vendrame F, Marchetti P, Dotta F. (2010) Islet inflammation and CXCL10 in recent-onset type 1 diabetes. *Clin Exp Immunol*; 159(3): 338-343. (I.F. 3.711)

Igoillo-Esteve M, Marselli L, Cunha DA, Ladrière L, Ortis F, Grieco FA, Dotta F, Weir GC, Marchetti P, Eizirik DL, Cnop M. (2010) Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. *Diabetologia*; 53(7): 1395-1405. (I.F. 7.113)

Dotta F, Galleri L, Sebastiani G, Vendrame F. (2010) Virus infections: lessons from pancreas histology. *Curr Diabetes Rep*; 10(5): 357-361. (I.F. 3.996)

Olivieri A, De Angelis S, Dionisi S, D'Annunzio G, Locatelli M, Marinaro M, Bonato V, Amendola A, Songini M, Velluzzi F, Schirru C, Cotichini R, Stazi MA, Dotta F, Lorini R, Bottazzo GF, Boirivant M. (2010) Serum transforming growth factor β 1 during diabetes development in non-obese diabetic mice and humans. *Clin Exp Immunol*; 162(3): 407-414. (I.F. 3.711)

Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R. (2010) Mechanisms of

impaired bone strength in type 1 and 2 diabetes. *Nutr Metab Cardiovas Dis*; 20(9): 683-690. (I.F. 3.340)

Gallwitz B, Haupt A, Kraus P, Peters N, Petto H, Dotta F, Petto H, Poll L, Rose L, Scherthaner G. (2010) Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al. *Diabetes Obes Metab*; 12(12): 1127-1128. (I.F. 6.133)

Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet*. 2010 Apr 24; 375(9724):1447-56. Erratum in: *Lancet*. 2010 Jul 24;376(9737):234. (I.F. 59.102)

Grieco FA, Vendrame F, Spagnuolo I, Dotta F. (2011) Innate immunity and the pathogenesis of type 1 diabetes. *Semin Immunopathol*; 33(1): 57-66. (I.F. 6.804)

Sebastiani G, Vendrame F, Dotta F. (2011) MicroRNAs as new tools for exploring type 1 diabetes: relevance for immunomodulation and transplantation therapy. *Transpl P*; 43(1): 330-332. (I.F. 0.959)

Falorni A, Chen S, Zanchetta R, Yu L, Tiberti C, Bacosi ML, Furmaniak J, Bini V, Dotta F, Eisenbarth GS, Smith BR, Betterle C. (2011) Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. *Clin Immunol*; 140(3): 291-299. (I.F. 3.548)

Sebastiani G, Grieco FA, Spagnuolo I, Galleri L, Cataldo D, Dotta F. (2011) Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. *Diabetes-Metab Res Rev*; 27(8): 862-866. (I.F. 4.758)

Grieco FA, Moretti M, Sebastiani G, Galleri L, Spagnuolo I, Scafetta G, Gulino A, De Smaele E, Maroder M, Dotta F. (2011) Delta-cell specific expression of hedgehog pathway Ptch1 receptor in murine and human endocrine pancreas. *Diabetes-Metab Res Rev*; 27(8): 755-760. (I.F. 4.758)

Bruno G, De Micheli A, Frontoni S, Monge L, Bonomo M, De Cosmo S, Grassi G, Nicolucci A, Aiello A, Bertuzzi F, Bonora E, Cimino A, Cordera R, de Bigontina G, Di Bartolo P, Dotta F, Frittitta L, Giaccari A, Giorgino F, Gruden G, Marchetti P, Meschi F, Pellegrini MA, Rivellesse A, Sesti G. (2011) Highlights from "Italian Standards of care for Diabetes Mellitus 2009-2010". *Nutr Metab Cardiovas Dis*; 21(4): 302-314. (I.F. 3.340)

Tancredi M, Marselli L, Lencioni C, Masini M, Bugliani M, Suleiman M, Masiello P, Boggi U, Filipponi F, Dotta F, Marchetti P, Di Cianni G. (2011) Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: A case report. *Islets*; 3(5): 231-233. (I.F. 1.879)

Tiberti C, Yu L, Lucantoni F, Panimolle F, Spagnuolo I, Lenzi A, Eisenbarth GS, Dotta F. (2011) Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. *Clin Exp*

Immunol; 166(3): 317-324. (I.F. 3.711)

Vendrame F, Dotta F. (2011) Comment on: Meagher et al. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. *Diabetes* 2010;59:2862-2871. *Diabetes*; 60(2): e12. (I.F. 7.199)

Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. (2011) Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. *J Hypertens*; 29(9): 1802-9. (I.F. 4.209)

Nicolucci A, Del Prato S, Vespasiani G; ELEONOR Study Group. (2011) Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. *Diabetes Care*; 34(12): 2524-6. (I.F. 15.270)

Grieco FA, Sebastiani G, Spagnuolo I, Patti A, Dotta F. (2012) Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. *Clin Exp Immunol*; 168(1): 24-29. (I.F. 3.711)

Vendrame F, Cataldo D, Ciarlo L, Umland O, Misasi R, Dotta F. (2012) In type 1 diabetes immunocompetent cells are defective in IL-16 secretion. *Scand J Immunol*; 75(1): 127-128. (I.F. 2.563)

Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, Roep BO, von Herrath MG. (2012) Demonstration of islet-autoreactive CD8 T cells in insulinitic lesions from recent onset and long-term type 1 diabetes patients. *J Exp Med*; 209(1): 51-60. (I.F. 10.892)

Del Prato S, Nicolucci A, Lovagnini-Scher AC, Turco S, Leotta S, Vespasiani G; ELEONOR Study Group. (2012) Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine—the ELEONOR study. *Diabetes Technol The*; 14(2): 175-82. (I.F. 4.488)

Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. *Diabetes Care*; 35(2): 252-8. (I.F. 15.270)

Gallo R, Natale M, Vendrame F, Boggi U, Filipponi F, Marchetti P, Laghi Pasini F, Dotta F. (2012) In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. *Acta Diabetol*; 49 Suppl 1: S123-31. PMID: 22249339. (I.F. 2.996)

Guarino E, Nigi L, Patti A, Fondelli C, Dotta F. (2012) Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. *Expert Opin Pharmacol*; 13(9): 1377-84. (I.F. 3.038)

Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R. (2012) Circulating sclerostin levels and

bone turnover in type 1 and type 2 diabetes. *J Clin Endocr Metab*; 97(5): 1737-1744. (I.F. 5.605)

Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, Dotta F, Rottiers P, Gysemans C, Mathieu C. (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified *Lactococcus lactis* in mice. *J Clin Invest*; 122(5): 1717-1725. (I.F. 12.282)

Gallwitz B, Guzman J, Dotta F, Guerci B, Simò R, Basson BR, Festa A, Kiljanski J, Sapin H, Trautmann M, Scherthaner G. (2012) Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. *Lancet*; 379(9833): 2270-2278. (I.F. 59.102)

Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA, Del Guerra S, D'Aleo V, Piro S, Marselli L, Boggi U, Filipponi F, Tinti L, Salvini L, Wollheim CB, Purrello F, Dotta F. (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. *Diabetologia*; 55(12): 3262-3272. (I.F. 7.113)

Galleri L, Sebastiani G, Vendrame F, Grieco FA, Spagnuolo I, Dotta F. (2012) Viral Infections and Diabetes. *Adv Exp Med Biol*; 771: 252-271. (I.F. 2.126)

Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). (2012) Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. *Nutr Metab Cardiovas Dis*; 22(11): 997-1006. (I.F. 3.340)

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaidis M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *New Engl J Med*; 367(23): 2204-13. (I.F. 70.670)

Rissanen A, Howard CP, Botha J, Thuren T, for the Global Investigators (2012) Effect of anti-IL-1 β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. *Diabetes Obes Metab*; 14:1088-1096. (I.F. 6.133)

Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani G, Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini S, Piemonti L, Marchetti P, Dotta F, Bosi E, Battaglia M. (2013) Reduced circulating neutrophils precedes and accompanies type 1 diabetes. *Diabetes*; 62(6): 2072-77. (I.F. 7.199)

Sebastiani G, Nigi L, Spagnuolo I, Morganti E, Fondelli C, Dotta F. (2013) MicroRNA profiling in sera of patients with type 2 diabetes mellitus reveals an upregulation of miR-31 expression in subjects with microvascular complications. *J Biomedical Science and Engineering (JBiSE)*; 6: 58-64. (I.F. 0.66)

Tortosa F, Dotta F. (2013) Incretin hormones and beta-cell mass

expansion: what we know and what is missing? *Arch Physiol Biochem*; 119(4):161-169. (I.F. 2.110)

Patti A, Gennari L, Merlotti D, Dotta F, Nuti R. (2013) Endocrine actions of osteocalcin. *Int J Endocrinol*; 2013:846480. (I.F.2.287)

Spagnuolo I, Patti A, Sebastiani G, Nigi L, Dotta F. (2013) The case for virus-induced type 1 diabetes. *Curr Opin Endocrinol Diabetes Obes*; 20(4):292-8. (I.F. 3.298)

Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events Study Group. (2013) HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. *Diabetes care*; 36(8): 2301-10. (I.F. 15.270)

Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) study group. (2013) Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. *J Intern Med*; 274(2): 176-191. (I.F. 6.051)

Bosi E, Scavini M, Ceriello A, Cucinotta D, Tiengo A, Marino R, Bonizzoni E, Giorgino F; PRISMA Study Group. (2013) Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. *Diabetes Care*; 36(10): 2887-94. (I.F. 15.270)

Ceccarelli E, Guarino E, Merlotti D, Patti A, Gennari L, Nuti R, Dotta F. (2013) Beyond glycemic control in diabetes mellitus: effects of incretin-based therapy on bone metabolism. *Front Endocrinol*; doi:10.3389/fendo.2013.00073; 4(73): 1-12. (I.F. 3.634)

Grieco FA, Moore F, Vigneron F, Santin I, Villate O, Marselli L, Rondas D, Overbergh L, Dotta F, Marchetti P, Mathieu C, Eizirik DL. (2013) IL-17A increases the expression of pro-inflammatory chemokines in human pancreatic islets. *Diabetologia*; 57(3): 502-511. (I.F. 7.113)

Mannucci E, Genovese S, Monami M, Navalesi G, Dotta F, Anichini R, Romagnoli F, Gensini G. (2014) Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study. The D.A.N.T.E. (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) Study. *Acta Diabetol*; 51(3): 435-40. (I.F. 2.996)

Tiberti C, Panimolle F, Bonamico M, Filardi T, Pallotta L, Nenna R, Pontone S, Dotta F, Pugliese G, Lenzi A, Balducci S, Morano S. (2014) Long-standing type 1 diabetes: patients with adult-onset develop celiac-specific immunoreactivity more frequently than patients with childhood-onset diabetes, in a disease duration-dependent manner. *Acta Diabetol*; 51(4):675-8. (I.F.2.996)

Dotta F, Sebastiani G. (2014) Enteroviral infections and development of type 1 diabetes: The Brothers Karamazov within the CVBs. *Diabetes*; 63(2): 384-6. (I.F. 7.199)

Takiishi T, Ding L, Baeke F, Spagnuolo I, Sebastiani G, Laureys J, Verstuyf A, Carmeliet G, Dotta F, Van Belle T, Gysemans C, Mathieu

C. (2014) Dietary supplementation with high doses of regular vitamin D3 safely reduces Diabetes incidence in nod mice when given early and long-term. *Diabetes*; 63(6): 2026-36. (I.F. 7.199)

Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, Van Huynegem K, Steidler L, Caluwaerts S, Demetter P, Wasserfall CH, Atkinson MA, Dotta F, Rottiers P, Van Belle TL, Mathieu C. (2014) Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by *Lactococcus lactis* reverses diabetes in recent-onset NOD mice. *Diabetes*; 63(8): 2876-87. (I.F. 7.199)

Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Penno G; RIACE Study Group. (2014) Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. *Cardiovasc Diabetol*;13(1): 59. (I.F. 5.948)

Cantara S, Pilli T, Sebastiani G, Cevenini G, Busonero G, Cardinale S, Dotta F, Pacini F. (2014) Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. *J Clin Endocr Metab*; 99(11):4190-8. (I.F. 5.605)

Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, Penno G, RIACE Study Group. (2014) Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. *Nutr Metab Cardiovas Dis*; 24(8): 815-22. (I.F. 3.340)

Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G; DIA3004 Study Group. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. *Diabetes Obes Metab*; 16(10):1016-27. (I.F. 6.133)

Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. *Lancet Diabetes Endo*; 2(11):885-93. (I.F. 24.540)

Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group. (2014) High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). *Eur J Endocrinol*; 171(6):697-704. (I.F.5.107)

Mathieu C, Overbergh L, Badenhoop K, Bingley P, Dayan C, Demengeot J, Dotta F, Eizirik D, Lenzen S, Marchetti P, Peakman M, Roep B, Todd J, Rottiers P, Megit S. (2014) The story of NAIMIT – A framework 7 project on type 1 diabetes. *Eur Endocrinol*; 10(2):100-105.

Sebastiani G, Po A, Miele E, Ventriglia G, Ceccarelli E, Bugliani M, Marselli L, Marchetti P, Gulino A, Ferretti E, Dotta F. (2015) MicroRNA-124a is hyperexpressed in type-2 diabetic human pancreatic islets and negatively regulates insulin secretion. *Acta Diabetol*; 52(3):523-30. (I.F. 2.996)

Buzzetti R, Spoletini ML, Zampetti S, Campagna G, Marandola L,

Panimolle F, Dotta F, Tiberti C for the NIRAD Study Group (NIRAD 8). (2015) Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. *Diabetes Care*; 38(3):513-20. (I.F.15.270)

Nicolucci A, Pintaudi B, Rossi MC, Messina R, Dotta F, Frontoni S, Caputo S, Lauro R. (2015) The social burden of Hypoglycemia in the elderly. *Acta Diabetol*; 52(4):677-85. (I.F. 2.996)

Pellegrini S, Ungaro F, Mercuri A, Melzi R, Sebastiani G, Dotta F, Broccoli V, Piemonti L, Sordi V. (2015) Human induced pluripotent stem cells differentiate into insulin-producing cells able to engraft in vivo. *Acta Diabetol*; 52(6):1025-35. (I.F. 2.996)

Scherthaner G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B. (2015) Treatment escalation options for patients with type 2 diabetes after failure of exenatide BID or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) Study. *Diabetes Obes Metab*; 17(7):689-698. (I.F. 6.133)

Ventriglia G, Nigi L, Sebastiani G, Dotta F. (2015) MicroRNAs: novel players in the dialogue between pancreatic islets and immune system in autoimmune diabetes. *Biomed Res Int*; 2015:749734. (I.F. 2.197)

Sebastiani G, Mancarella F, Ventriglia G, Nigi L, Valentini M, Grieco GE, Dotta F. (2015) MicroRNA miR-124a, a negative regulator of insulin secretion, is hyperexpressed in human pancreatic islets of type 2 diabetic patients. *RNA & DISEASE*; 2: e593. DOI: 10.14800/rd.593.

Simó R, Guerci B, Scherthaner G, Gallwitz B, Rosas-Guzmán J, Dotta F, Festa A, Zhou M, Kiljański J. (2015) Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. *Cardiovasc Diabetol*; 14:116. DOI 10.1186/s12933-015-0279-z. (I.F. 5.948)

Martino L, Masini M, Bugliani M, Marselli L, Suleiman M, Boggi U, Nogueira TC, Filipponi F, Occhipinti M, Campani D, Dotta F, Syed F, Eizirik DL, Marchetti P, De Tata V. (2015) Mast cells infiltrate pancreatic islets in human type 1 diabetes. *Diabetologia*; 58(11):2554-62. (I.F. 7.113)

Battaglia M, Nigi L, Dotta F. (2015) Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset? *Curr Diabetes Rep*; 15(12):115. doi: 10.1007/s11892-015-0690-6. (I.F. 3.996)

Belba A, Cortelazzo A, Giansanti A, Durante J, Nigi L, Dotta F, Timperio AM, Zolla L, Leoncini R, Guerranti R, Ponchiatti R. (2016) Erectile dysfunction and diabetes: association with the impairment of lipid metabolism and oxidative Stress. *Clin Biochem*; 49(1):70-8. (I.F. 2.430)

Laiho JE, Oikarinen M, Richardson SJ, Frisk G, Nyalwidhe J, Burch TC, Morris MA, Oikarinen S, Pugliese A, Dotta F, Campbell-Thompson M, Nadler J, Morgan NG, Hyöty H, JDRF nPOD-Virus Group. (2016) Relative sensitivity of immunohistochemistry, multiple reaction monitoring mass spectrometry, in situ hybridization and PCR to detect Coxsackievirus B1 in A549 cells. *J Clin Virol*; 77:21-8. doi:

10.1016/j.jcv.2016.01.015. (I.F. 3.020)

Grieco FA, Sebastiani G, Juan-Mateu J, Villate O, Marroqui L, Ladrière L, Tugay K, Regazzi R, Bugliani M, Marchetti P, Dotta F, Eizirik DL. (2016) MicroRNAs miR-23a-3p, miR-23b-3p and miR-149-5p Regulate the Expression of Pro-Apoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic Beta Cells. *Diabetes*; 66(1):100-112. (I.F. 7.199)

Vitale M, Masulli M, Rivellesse AA, Bonora E, Cappellini F, Nicolucci A, Squatrito S, Antenucci D, Barrea A, Bianchi C, Bianchini F, Fontana L, Fornengo P, Giorgino F, Gnasso A, Mannucci E, Mazzotti A, Nappo R, Palena AP, Pata P, Perriello G, Potenziani S, Radin R, Ricci L, Romeo F, Santini C, Scarponi M, Serra R, Timi A, Turco AA, Vedovato M, Zavaroni D, Grioni S, Riccardi G, Vaccaro O; TOSCA.IT Study Group. (2016) Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. *Eur J Nutr*; 57(2):679-688. doi: 10.1007/s00394-016-1355-1. (I.F.4.449)

Takiishi T, Cook DP, Korf H, Sebastiani G, Mancarella F, Mori Cunha JPMC, Wasserfall C, Casares N, Lasarte JJ, Steidler L, Rottiers P, Dotta F, Gysemans C, Mathieu C. (2017) Reversal of Diabetes in NOD Mice by Clinical-Grade Pro-Insulin and IL10 Secreting *Lactococcus Lactis* in Combination with Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. *Diabetes*; 66(2):448-459. doi: 10.2337/db15-1625. (I.F. 7.199)

Sebastiani G, Valentini M, Grieco GE, Ventriglia G, Nigi L, Mancarella F, Pellegrini S, Martino G, Sordi V, Piemonti L, Dotta F. (2017) MicroRNA expression profiles of human iPSCs differentiation into insulin-producing cells. *Acta Diabetol*;54(3):265-281. doi: 10.1007/s00592-016-0955-9. (I.F. 2.996)

Sebastiani G, Nigi L, Grieco GE, Mancarella F, Ventriglia G, Dotta F. (2017) Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis and staging? *J Endocrinol Invest*; 40(6):591-610. doi: 10.1007/s40618-017-0611-4. (I.F. 3.439)

Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. (2017) Dapagliflozin modulates glucagon secretion in a SGLT2-independent manner in murine alpha-cells. *Diabetes Metab*; 43(6):512-520. doi: 10.1016/j.diabet.2017.04.002. (I.F. 4.008)

Sebastiani G, Ventriglia G, Stabilini A, Socci C, Morsiani C, Laurenzi A, Nigi L, Formichi C, Mfarrej B, Petrelli A, Fousteri G, BruskoTM, Dotta F, Battaglia M. (2017) Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. *Sci Rep*; 7(1):6897. doi: 10.1038/s41598-017-07172-1 (I.F.4.011)

Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellesse AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G, for the Thiazolidinediones Or Sulfonyleureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group. (2017) Effects on the

incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol*; 5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. (I.F. 24.540)

Lenzi A, Dotta F, Frontoni S, Crialesi R, Nicolucci A, Vaccaro K. (2017) Il progetto Cities Changing Diabetes. *L'Endocrinologo*; 18:203-207. DOI: 10.1007/s40619-017-0352-9.

Sebastiani G, Guarino E, Grieco GE, Formichi C, Delli Poggi C, Ceccarelli E, Dotta F. (2017) Circulating microRNA(miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of microRNA miR-330-3p. *Front Endocrinol*; 8:345. doi: 10.3389/fendo.2017.00345 (I.F. 3.634)

Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. (2018) Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, Randomized Clinical Trial. *Diabetes Care*; 41(2):258-266. doi: 10.2337/dc17-0417. (I.F. 15.270)

Nigi L, Fondelli C, de Donato G, Palasciano G, Setacci C, Dotta F. (2018) Fighting diabetic foot ulcers-The diabetologist: A king maker of the fight. *Semin Vasc Surg*. 31(2-4):49-55. doi: 10.1053/j.semvascsurg.2018.12.003. (I.F. 1.568)

De Donato G, Pasqui E, Setacci F, Palasciano G, Nigi L, Fondelli C, Sterpetti A, Dotta F, Weber G, Setacci C. (2018) Acute on chronic limb ischemia: From surgical embolectomy and thrombolysis to endovascular options. *Semin Vasc Surg*; 31(2-4):66-75. doi:10.1053/j.semvascsurg.2018.12.008. (I.F. 1.568)

Culina S, Lalanne AI, Afonso G, Cerosaletti K, Pinto S, Sebastiani G, Kuranda K, Nigi L, Eugster A, Østerbye T, Maugein A, McLaren JE, Ladell K, Larger E, Beressi JP, Lissina A, Appay V, Davidson HW, Buus S, Price DA, Kuhn M, Bonifacio E, Battaglia M, Caillat-Zucman S, Dotta F, Scharfmann R, Kyewski B, Mallone R and the ImMaDiab Study Group (2018) Islet-reactive CD8+ T-cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. *Sci Immunol*; 3(20). pii:eaao4013. doi: 10.1126/sciimmunol.aao4013. (I.F. 10.551)

Catanzaro G, Besharat ZM, Chiacchiarini M, Abballe L, Sabato C, Vacca A, Borgiani P, Dotta F, Tesaro M, Po A, Ferretti E. (2018) Circulating microRNAs in elderly type 2 diabetic patients. *Int J Endocrinol*;2018:6872635. doi: 10.1155/2018/6872635. (I.F.2.287)

Sebastiani G, Ceccarelli E, Castagna MG, Dotta F. (2018) G-protein coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives. *Best Pract Res Clin Endocrinol Metab*; 32(2):201-213. doi: 10.1016/j.beem.2018.02.005. (I.F. 3.808)

Guarino E, Delli Poggi C, Grieco GE, Cenci V, Ceccarelli E, Crisci I, Sebastiani G, Dotta F. (2018) Circulating MicroRNAs as biomarkers of Gestational Diabetes Mellitus: updates and perspectives. *Int J Endocrinol*; 2018:6380463. doi: 10.1155/2018/6380463. (I.F. 2.287)

Sebastiani G, Grieco GE, Brusco N, Ventriglia G, Formichi C, Marselli L, Marchetti P, Dotta F. (2018) MicroRNAs Expression Analysis of in Vitro Differentiated Human Pancreatic Islet Cells Reveals the

Activation of the Pluripotency-Related MicroRNA Cluster miR-302s. *Int J Mol Sci*; 19(4). pii: E1170. doi: 10.3390/ijms19041170. (I.F. 4.183)

Dotta F, Ventriglia G, Snowwhite IV, Pugliese A. (2018) MicroRNAs: Markers of β -cell stress and autoimmunity. *Curr Opin Endocrinol Diabetes*; 25(4):237-245. doi: 10.1097/MED.0000000000000420. (I.F. 3.298)

Ifie E, Russell MA, Dhayal S, Leete P, Sebastiani G, Nigi L, Dotta F, Marjomäki V, Eizirik DL, Morgan NG, Richardson SJ. (2018) Unexpected subcellular distribution of a specific isoform of the Cocksackie and Adenovirus Receptor, CAR-SIV, in human pancreatic beta cells. *Diabetologia*; 61(11):2344-2355. doi: 10.1007/s00125-018-4704-1. (I.F. 7.113)

Gonzalez-Duque S, Azoury ME, Colli ML, Afonso G, Turatsinze JV, Nigi L, Lalanne AI, Sebastiani G, Carré A, Pinto S, Culina S, Corcos N, Bugliani M, Marchetti P, Armanet M, Diedisheim M, Kyewski B, Steinmetz LM, Buus S, You S, Dubois-Laforgue D, Larger E, Beressi JP, Bruno G, Dotta F, Scharfmann R, Eizirik DL, Verdier Y, Vinh J, Mallone R. (2018) Conventional and Neo-Antigenic Peptides Presented by β Cells Are Targeted by Circulating Naïve CD8+ T Cells in Type 1 Diabetic and Healthy Donors. *Cell Metab*; 28(6):946-960.e6. doi: 10.1016/j.cmet.2018.07.007. (I.F. 22.415)

Egan CG, Fondelli C, Pierantozzi E, Tripepi G, Dotta F, Sorrentino V. (2018) Putative endothelial progenitor cells predict long-term mortality in type-2 diabetes. *Endocrine*; 62(1):263-266. doi: 10.1007/s12020-018-1695-0. (I.F. 3.296)

Guay C, Kruit JK, Rome S, Menoud V, Mulder NL, Jurdzinski A, Mancarella F, Sebastiani G, Donda A, Gonzalez BJ, Jandus C, Bouzakri K, Pinget M, Boitard C, Romero P, Dotta F, Regazzi R. (2018) Lymphocyte-derived exosomal microRNAs promote pancreatic β -cell death and may contribute to type 1 diabetes development. *Cell Metab*; 29(2):348-361.e6. doi: 10.1016/j.cmet.2018.09.011. (I.F. 22.415)

Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, Rancoita PM, Cugnata F, Mandelli A, Valle A, Leete P, Mancarella F, Linsley PS, Krogvold L, Herold KC, Elding Larsson H, Richardson SJ, Morgan NG, Dahl-Jørgensen K, Sebastiani G, Dotta F, Bosi E, the DRI_Biorepository Group, the Type 1 Diabetes TrialNet Study Group, Battaglia M. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. *JCI Insight*; 3(18). pii:122146. doi. 10.1172/jci.insight122146. (I.F. 6.014)

Nigi L, Grieco GE, Ventriglia G, Brusco N, Mancarella F, Formichi C, Dotta F*, Sebastiani G. (2018) MicroRNAs as regulators of insulin signaling: research updates and potential therapeutic perspectives in type 2 Diabetes. *Int J Mol Sci*;19(12). pii: E3705. doi: 10.3390/ijms19123705. (I.F. 4.183)

Grieco GE, Cataldo D, Ceccarelli E, Nigi L, Catalano G, Brusco N, Mancarella F, Ventriglia G, Fondelli C, Guarino E, Crisci I, Sebastiani G,* Dotta F (2018) Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism. *Non-Coding RNA*; 4(4). Pii: E37. doi. 10.3390/ncrna4040037.

Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, Dauriz M, Dotta F, Formichi C, Frontoni S, Invitti C, Orsi E, Picconi F,

Resi V, Bonora E, Purrello F. (2019) Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. *Acta Diabetol*; 56(6):605-617. doi: 10.1007/s00592-018-1271-3. (I.F. 2.996)

Solini A, Penno G, Orsi E, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Baroni MG, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. (2019) Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study. *BMC Med*; 17(1):83. doi: 10.1186/s12916-019-1313-x. (I.F. 8.285)

Nicolucci A, Rossi MC, Vaccaro K, Crialesi R, Rossetti S, Da Empoli S, Corsaro L, Morviducci L, Baroni MG, Frontoni S, Dotta F. (2019) Urban diabetes: the case of the metropolitan area of Rome. *Acta Biomed*; 90(2):209-214. doi: 10.23750/abm.v90i2.8345.

Marchetti P, Schulte AM, Marselli L, Schoniger E, Bugliani M, Kramer W, Overbergh L, Ullrich S, Gloyn AL, Ibberson M, Rutter G, Froguel P, Groop L, McCarthy MI, Dotta F, Scharfmann R, Magnan C, Eizirik DL, Mathieu C, Cnop M, Thorens B, Solimena M. (2019) Fostering improved human islet research: a European perspective. *Diabetologia*; 62(8):1514-1516. doi: 10.1007/s00125-019-4911-4. (I.F. 7.113)

Evangelista I, Nuti R, Piccioni T, Dotta F, Palazzuoli A. (2019) Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. *Int J Mol Sci*; 20(13). pii: E3264. doi: 10.3390/ijms20133264. Review. (I.F. 4.183)

Ventriglia G, Mancarella F, Sebastiani G, Cook FP, Mallone R, Mathieu C, Gysemans C, Dotta F. (2019) miR-409-3p is reduced in plasma and in islet immune infiltrates of NOD diabetic mice and is differentially expressed in type 1 diabetic patients. *Diabetologia*. In press (I.F. 7.113)

Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E; PIONEER 2 Investigators. (2019) Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. *Diabetes Care*. pii: dc190883. doi: 10.2337/dc19-0883. (I.F. 15.270)

Il CV è compilato dall'interessato e periodicamente aggiornato sotto la sua diretta responsabilità